Dangerous dual-use dilemma of AI in biological research, where the same technology capable of curing cancer could enable bioweapons development.
It reveals that 73% of AI safety experts see significant bioweapon risks within the next decade. The piece examines OpenAI's admission about heightened biological weapon risks in their models, the $64 billion AI industry's regulatory challenges, and fragmented global oversight.
It discusses tech giants' self-regulation efforts through refusal mechanisms and safety measures, while questioning whether perfect AI biosecurity is achievable. The blog concludes that we're conducting a global experiment with technology that could either save or doom humanity.
